| HEB - Hemispherx Biopharma Inc (Healthcare: Biotechnology) | Projected Earnings Date: 2017-08-18 (Delayed quote data 2025-04-03) |
|
|
|||||||||||||||||
|
|
|
| Company Profile | |
| Hemispherx Biopharma Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the experimental therapeutic Ampligen. Alferon N Injection is approved for a category of STD infection, and Ampligen represents a RNA being developed for viral diseases and disorders of the immune system. The business segment of the firm is to perform research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The sales revenue of the company is derived from the United States. | |
| Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |